



News release
24 March 2016

***Maxigesic IV* IND Approved by FDA**

Australia and New Zealand pharmaceutical company, AFT Pharmaceuticals, has today announced that the IND [Investigational New Drug Application] for Maxigesic IV has now been approved by the US FDA on 22nd March 2016.

This is the first key step in the regulatory process to seek approval for Maxigesic IV in the USA. The first clinical pharmacokinetic study conducted under the IND in CCST, Christchurch, New Zealand has now been opened and patient enrolment will commence in April.

[End of release]

Contact:

Malcolm Tubby
Chief Financial Officer
AFT Pharmaceuticals Ltd
Phone: +64 9 488 0232 (x703)
Mobile: +64 21 36 88 69
Email: malcolm@aftpharm.com